These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 29804932)

  • 21. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease.
    Raben N; Baum R; Schreiner C; Takikita S; Mizushima N; Ralston E; Plotz P
    Autophagy; 2009 Jan; 5(1):111-3. PubMed ID: 19001870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand..
    Raben N; Takikita S; Pittis MG; Bembi B; Marie SK; Roberts A; Page L; Kishnani PS; Schoser BG; Chien YH; Ralston E; Nagaraju K; Plotz PH
    Autophagy; 2007; 3(6):546-52. PubMed ID: 17592248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
    Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten.
    Raben N; Wong A; Ralston E; Myerowitz R
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):13-21. PubMed ID: 22253254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease.
    Spampanato C; Feeney E; Li L; Cardone M; Lim JA; Annunziata F; Zare H; Polishchuk R; Puertollano R; Parenti G; Ballabio A; Raben N
    EMBO Mol Med; 2013 May; 5(5):691-706. PubMed ID: 23606558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease.
    Nilsson MI; MacNeil LG; Kitaoka Y; Suri R; Young SP; Kaczor JJ; Nates NJ; Ansari MU; Wong T; Ahktar M; Brandt L; Hettinga BP; Tarnopolsky MA
    Free Radic Biol Med; 2015 Oct; 87():98-112. PubMed ID: 26001726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease.
    Lim JA; Li L; Kakhlon O; Myerowitz R; Raben N
    Autophagy; 2015; 11(2):385-402. PubMed ID: 25758767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy in the mouse model of Pompe disease.
    Raben N; Danon M; Gilbert AL; Dwivedi S; Collins B; Thurberg BL; Mattaliano RJ; Nagaraju K; Plotz PH
    Mol Genet Metab; 2003; 80(1-2):159-69. PubMed ID: 14567965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.
    Raben N; Ralston E; Chien YH; Baum R; Schreiner C; Hwu WL; Zaal KJ; Plotz PH
    Mol Genet Metab; 2010 Dec; 101(4):324-31. PubMed ID: 20801068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
    Han SO; Li S; Koeberl DD
    Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders.
    Ullman JC; Mellem KT; Xi Y; Ramanan V; Merritt H; Choy R; Gujral T; Young LEA; Blake K; Tep S; Homburger JR; O'Regan A; Ganesh S; Wong P; Satterfield TF; Lin B; Situ E; Yu C; Espanol B; Sarwaikar R; Fastman N; Tzitzilonis C; Lee P; Reiton D; Morton V; Santiago P; Won W; Powers H; Cummings BB; Hoek M; Graham RR; Chandriani SJ; Bainer R; DePaoli-Roach AA; Roach PJ; Hurley TD; Sun RC; Gentry MS; Sinz C; Dick RA; Noonberg SB; Beattie DT; Morgans DJ; Green EM
    Sci Transl Med; 2024 Jan; 16(730):eadf1691. PubMed ID: 38232139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutritional co-therapy with 1,3-butanediol and multi-ingredient antioxidants enhances autophagic clearance in Pompe disease.
    Nilsson MI; Crozier M; Di Carlo A; Xhuti D; Manta K; Roik LJ; Bujak AL; Nederveen JP; Tarnopolsky MG; Hettinga B; Meena NK; Raben N; Tarnopolsky MA
    Mol Genet Metab; 2022; 137(1-2):228-240. PubMed ID: 35718712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease.
    Bijvoet AG; van de Kamp EH; Kroos MA; Ding JH; Yang BZ; Visser P; Bakker CE; Verbeet MP; Oostra BA; Reuser AJ; van der Ploeg AT
    Hum Mol Genet; 1998 Jan; 7(1):53-62. PubMed ID: 9384603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.